Acta Med. 2012, 55: 74-77

https://doi.org/10.14712/18059694.2015.58

Preoperative Serum Levels of Soluble Endoglin for Prediction of Recurrence in Stage III Colorectal Cancer Patients

Ismail Gomcelia, Mesut Tezb, Erdal B. Bostancia, Nesrin Turhanc, Ahu S. Kemikd, Musa Akoglua

aTurkiye Yuksek Ihtisas Education and Research Hospital, Department of Gastroenterologic Surgery, Ankara, Turkey
bAnkara Numune Education and Research Hospital, Department of General Surgery, Ankara, Turkey
cTurkiye Yuksek Ihtisas Education and Research Hospital Department of Pathology, Ankara, Turkey
dIstanbul University Cerrahpasa Medical Faculty, Department of Biochemistry, Istanbul, Turkey

Received October 20, 2011
Accepted May 9, 2012

References

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. E stimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18: 581–592. <https://doi.org/10.1093/annonc/mdl498>
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476–487. <https://doi.org/10.1056/NEJMra040958>
3. Allegra CJ, Paik S, Colangelo LH, Parr AL , Kirsch I, Kim G, Klein P, Johnston PG , Wolmark N, Wieand HS. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003; 21: 241–50. <https://doi.org/10.1200/JCO.2003.05.044>
4. Mysliwiec P, Pawlak K, Bandurski R, Kedra B. Soluble angiogenesis markers in gastric tumor patients. Folia Histochem Cytobiol. 2009; 47: 81–6.
5. Nikiteas NI, Tzanakis N, Theodoropoulos G, Atsaves V, Christoni Z, Karakitsos P, et al.Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer. 2007; 10: 12–7. <https://doi.org/10.1007/s10120-006-0401-8>
6. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001; 7: 524–32.
7. Myśliwiec P, Pawlak K, Kukliński A, Kedra B. Combined perioperative plasma endoglin and VEG F-A assessment in colorectal cancer patients. Folia Histochem Cytobiol. 2008; 46: 487–92.
8. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP 160 defined by monoclonal antibody SN 6. Proc Natl Acad Sci U.S.A. 1986; 83: 7898–902. <https://doi.org/10.1073/pnas.83.20.7898> <PubMed>
9. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004; 2: 18. <https://doi.org/10.1186/1479-5876-2-18> <PubMed>
10. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004; 17: 197–203. <https://doi.org/10.1038/modpathol.3800034>
11. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery. 2002; 131: S109–113. <https://doi.org/10.1067/msy.2002.119361>
12. Li C, Guo B, Wilson P, Stewart A, Byrne G, Bundred N, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000; 89: 122–126. <https://doi.org/10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M>
13. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001; 7: 524–532.
14. Li C, Gardy R, Seon BK, Duff SE , Abdalla S, Renehan A, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003; 88: 1424–1431. <https://doi.org/10.1038/sj.bjc.6600874> <PubMed>
15. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, Osada S, Ichikawa Y, Shimada H. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008; 15: 3433–9. <https://doi.org/10.1245/s10434-008-0168-8>
16. Chen SL, Steele SR, Eberhardt J, Zhu K, Bilchik A, Stojadinovic A. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg. 2011; 253: 82–7. <https://doi.org/10.1097/SLA.0b013e3181ffa780>
17. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2000; 23: 8706–8712. <https://doi.org/10.1200/JCO.2005.02.8852>
18. Lee HY, Choi HJ, Park KJ, et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol. 2007; 14: 1712–1717. <https://doi.org/10.1245/s10434-006-9322-3>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive